TechNote12_SM_Images.jpg TechNote14_Banners_SM.jpg

 

COVID-19 Research page

Get ahead in the race to understand the Coronavirus with the WAVEsystem

The coronavirus outbreak is posing a threat to our health, economy and mobility. The Creoptix WAVEsystem offers a platform for studying the binding kinetics of antibodies to viral proteins based on the sensitive Grating-Coupled Interferometry (GCI) technology. With no-clog and disposable sensor chips, the WAVEsystem enables the robust characterization of kinetics on both small molecules and biologics. You can work safely and avoid cross-contamination between experiments, as well as be confident about your kinetic data and accelerate your vaccine research and development.

KINETIC CHARACTERIZATION OF ANTIBODIES IN (UN)DILUTED PLASMA FOR INSIGHTS INTO COVID-19 DISEASE MECHANISMS 

 
With high sensitivity and innovative disposable, no-clog microfluidics for very high tolerance against crude matrixes, the WAVEsystem has the potential to overcome the limitations associated with traditional label-free surface-based biosensors.
 
In our latest TechNote, in collaboration with Prof. Adriano Aguzzi (Professor for Neuropathology, University of Zurich), we show how the WAVEsystem enables the kinetic characterization of SARS-CoV-2 antibodies to three specific antigens in diluted human plasma. The robust microfluidics of the system allow similar measurements at higher plasma (and serum) concentrations, thereby opening the door for antibody quantification without the need for dilution, which is often responsible for the perceived limited limit of detection of traditional label-free technologies, and orthogonal validation of ELISA data.
 
"Antibody characterization from COVID-19 patient plasma binding to SARS-CoV-2 antigens", is available here.
 
Figure_Web_TechNote12.jpg
 

ACCELERATING THE DEVELOPMENT OF THERAPEUTICS AGAINST
SARS-COV-2 

 
With superior sensitivity to conventional Surface Plasmon Resonance (SPR) technologies for more accurate measurement of binding affinity and binding kinetics, the Creoptix™ WAVEsystem is driving biologics development.

Synthetic single-domain antibodies (also known as nanobodies or sybodies) could be key to the development of COVID-19 preventive treatments given their suitability for pulmonary delivery in the form of inhaled nanobody formulations. Using the WAVEsystem, the group of Prof. Markus Seeger at the University of Zurich recently identified six unique sybodies with favourable binding affinity to the receptor-binding domain (RBD) of SARS-CoV-2 spike protein. In agreement with ELISA data – yet providing on- and off-rates for more kinetic details – our GCI technology revealed that co-injection of a pair of 2 sybodies results in a clear increase of the response signal, suggesting a simultaneous binding to RBD, characteristic of non-overlapping binders.

covurve.jpg

Discover how Prof. Seeger’s in vitro selection platform was used to select sybodies from three large combinatorial libraries in twelve (12) days, and how the WAVEsystem shed light on the best candidates in just two days here.

We’ve extended this study in TechNote 14: Shedding light on sybodies binding onto SARS-CoV-2 spike RBD, carried out in collaboration with leadXpro and the University of Zurich. Discover how the WAVEsystem can be used to understand the dynamics of a sybody binding onto the receptor binding domain (RBD) region of the SARS-CoV-2 Spike protein. With high sensitivity and robust microfluidics, the WAVEsystem is suitable for competition assays, confirming and enriching ELISA data. By providing a rapid kinetic characterization for inhibition assays, the WAVE is accelerating the development of therapeutics against SARS-CoV-2. Read all about it here.

AVOID THE RISK OF ANTIBODY-BASED ASSAY FAILURE WITH THE CREOPTIX WAVEsystem

The Creoptix™ WAVEsystem allows researchers to avoid the risk of antibody-based assay failure by providing robust evaluation of antibody pairs, ideal for lateral-flow test development. Profiling individual antibodies in both buffer and serum/plasma prior to assay development delivers improved understanding of antibody performance and stability to guide reagent selection for more reliable ELISA results.

More than buffer
Profile the stability and performance of individual antibodies in a range of physiologically relevant media, including biofluids such as serum and plasma with our patented no-clog microfluidics technology

Identify the most effective antibody pairs
Explore various pairing possibilities and operate within the widest range of binding kinetics on the market

“Understanding the dynamics of our detection reagents in complex matrices presents a big challenge when developing new assay platforms, particularly as we advance the limits of sensitivity with novel amplification technologies. The WAVEdelta system opens up new exciting opportunities for the project by giving us a real-time view of these interactions. The impressive detection range and versatility of the system will be a huge asset as the project progresses”

James Schouten, Principal Scientist at Mologic

Read more about our recently announced collaboration with Prof. Adriano Aguzzi (Professor for Neuropathology, University of Zurich) to characterize immunological responses to SARS-CoV-2 and provide new insights in serological testing here."
 

VIRUS-LIKE PARTICLES PRESENT UNIQUE CHALLENGES 

 
Virus-like particles (VLPs) represent an effective vaccine platform with potential to induce immune responses. A limitation of this approach is that the resultant size of these structures, combined with a tendency to aggregate, can cause microfluidics channels to clog. Impeded flow may lead to experimental delays and can also increase instrument maintenance costs, however the Creoptix® WAVEsystem overcomes this issue by incorporating a unique, no-clog microfluidic design. 

ANALYZE LARGE MOLECULES AND BENEFIT FROM LOWER DETECTION LIMITS WITH THE CREOPTIX™ WAVEsystem 

No clogging, regardless of size
Take advantage of the Creoptix™ WAVEsystem’s no-clog microfluidics to analyze and characterize larger molecules.

High sensitivity
Explore lower limits of detection with our GCI technology and resolve kinetics at low responses.
  
 

6af3103d-5b3c-4da9-a4fb-1368310892b2.jpg